Upstart Akero continues its swoosh into NASH space with $70M windfall round
Akero Therapeutics first swooshed onto the NASH stage with a drug in-licensed from Amgen, recruiting Gilead’s Andrew Cheng as CEO several months later and making a cross-country move to San Francisco. Now, it’s capping an eventful year with $70 million more to bankroll its Phase II work and scale the operations considerably.
Led by Janus Henderson Investors, the Series B comes just six months after Akero launched with $65 million in Series A cash, suggesting that an IPO could be in sight.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
